← Back to Search

Single arm for Dry Eye Syndrome

Phase 1 & 2
Waitlist Available
Led By Daniel C Brocks, MD
Research Sponsored by Boston Sight
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month
Awards & highlights

Study Summary

This trial is testing if a medication for dry eyes is safe to use with a type of contact lens. Early results suggest it is effective for treating dry eye symptoms.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Subjects symptoms
visual function

Side effects data

From 2014 Phase 2 trial • 102 Patients • NCT01817582
9%
Eye Irritation
6%
Instillation Site Pain
6%
Eye Pruritus
100%
80%
60%
40%
20%
0%
Study treatment Arm
Lotemax Gel 0.5% and Restasis 0.05%
Lotemax Gel 0.5%
Restasis 0.05%

Trial Design

1Treatment groups
Experimental Treatment
Group I: Single armExperimental Treatment1 Intervention
All subjects will receive Restasis in this study
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Restasis
2013
Completed Phase 4
~1020

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Boston SightLead Sponsor
5 Previous Clinical Trials
103 Total Patients Enrolled
AllerganIndustry Sponsor
781 Previous Clinical Trials
276,559 Total Patients Enrolled
Daniel C Brocks, MD4.810 ReviewsPrincipal Investigator - Boston Sight
Boston Sight
3Patient Review
DR Brocks is recommended for his knowledge and effectiveness. He listens and cares. His assistant, however, is consistently unfriendly, making it unpleasant to be in the office. The rest of the staff is much more pleasant and helpful.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants have enrolled in the research project thus far?

"Yes, the information provided on clinicaltrials.gov shows that this medical trial is now enrolling participants. This study was posted on July 15th 2021 and its most recent updates were implemented on March 6th 2022. It aims to recruit 10 patients from a single site."

Answered by AI

Are there still availabilities for participants in this research?

"Affirmative. Data hosted on clinicaltrials.gov affirms that this investigation, which was first posted on July 15th 2021, is actively enrolling patients. Precisely 10 subjects need to be enlisted from a single medical centre."

Answered by AI

Are there any analogous investigations that have previously addressed this therapy?

"Currently, 67 clinical studies are examining this particular treatment with 12 of them in the advanced Phase 3. While most of these trials occur in Aurora, Colorado, there exist 470 other sites looking into it."

Answered by AI

For what maladies is this medication commonly prescribed?

"Through this intervention, it is possible to manage transplantation side effects, over-production of tears and lupus nephritis."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% on Application of PROSE Devices for Management of Patients With Ocular Surface Disease
Daniel C Brocks 2021. "Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% on Application of PROSE Devices for Management of Patients With Ocular Surface Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04918823.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top